Insmed Incorporated (NASDAQ:INSM) Stock Position Increased by Hood River Capital Management LLC

Hood River Capital Management LLC raised its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 3.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,525,628 shares of the biopharmaceutical company's stock after purchasing an additional 53,073 shares during the quarter. Insmed accounts for about 1.6% of Hood River Capital Management LLC's holdings, making the stock its 10th biggest holding. Hood River Capital Management LLC owned approximately 0.85% of Insmed worth $105,329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in Insmed in the fourth quarter worth $126,606,000. Vanguard Group Inc. increased its position in shares of Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares during the last quarter. Capital International Investors raised its holdings in shares of Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after buying an additional 593,206 shares in the last quarter. B Group Inc. bought a new stake in Insmed in the 4th quarter worth approximately $24,164,000. Finally, Marshall Wace LLP boosted its stake in Insmed by 38.0% in the fourth quarter. Marshall Wace LLP now owns 1,064,215 shares of the biopharmaceutical company's stock worth $73,473,000 after buying an additional 293,004 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have recently weighed in on INSM. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a report on Wednesday, March 19th. JPMorgan Chase & Co. boosted their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 price objective on shares of Insmed in a research note on Tuesday, April 22nd. Truist Financial raised their price target on shares of Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $94.00.

Insmed Stock Down 0.7 %

Shares of Insmed stock traded down $0.46 during midday trading on Monday, hitting $69.23. The company had a trading volume of 1,583,682 shares, compared to its average volume of 2,303,980. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company has a 50 day moving average of $74.38 and a 200 day moving average of $73.57. The stock has a market capitalization of $12.59 billion, a P/E ratio of -12.41 and a beta of 1.07.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, equities analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total transaction of $479,192.80. Following the transaction, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at $16,412,107.84. The trade was a 2.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares of the company's stock, valued at $7,766,640. This represents a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 471,797 shares of company stock worth $37,621,239. Insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.